健骨胶囊对兔骨性关节炎软骨及滑膜病变的影响
|
摘要
目的:研究骨性关节炎(OA)的中医病因病机,探讨健骨胶囊对实验性OA软骨及滑膜病变影响的作用机理。方法:以木瓜蛋白酶膝关节腔内注射法建立兔OA模型,以西药维固力为对照药物,观察健骨胶囊对动物模型关节软骨、滑膜组织形态学及软骨、滑膜中基质金属蛋白酶(matrix metalloproteinases,MMP)-1、3、金属蛋白酶组织抑制剂(tissue inhibitor sofmatrix metallo proteinase, TIMP)-1、白细胞介素-1β(IL-1β)表达的影响。结果:健骨胶囊组兔滑膜及软骨组织形态学改变与模型组比较明显较轻(P<0.01);滑膜、软骨中MMP-1、MMP-3、IL-1β表达减少,与模型组比较有非常显著性差异(P<0.01),TIMP-1表达增加,与模型组比较有显著性差异(P<0.05);与维固力组相比在降低IL-1β表达方面差异呈显著性(P<0.05),其他指标无显著差异(P>0.05)。结论:健骨胶囊能够减轻兔OA模型的软骨退行性变和滑膜炎症,其作用机理可能与下调IL-1β水平,调节MMP-1、MMP-3、TIMP-1表达有关。
Objective: To study epidemiology and pathogenesis of osteoarthritis(OA) in TCM, and to study the effect of Jiangu capsules on pathology of cartilage and synovia of OA on experimental rabbits.
Methods: Make the OA models by injecting papain to the knees of experimental rabbits. Select Glucosamine Sulfate Capsules as the control group. Observe the effection of histology of joint cartilage and synovia, and the levels of matrix metalloproteinases(MMP)-1,3, tissue inhibitor sofmatrix metalloproteinases (TIMP) -1, interleukin(IL)-1βin cartilage and synovia.
Results: The histology changes of cartilage and synovia were lighter in Jiangu capsules group than that in model group (p<0.01). The levels of MMP-1,MMP-3, IL-1βin cartilage and synovia were decrease and level of TIMP-1 was increase. It showed significant different in Jiangu capsule group and the model group( p<0.01 or p<0.05).The level of IL-1βshowed significant different (p<0.05) and others showed insignificant different (p>0.05) in Jiangu capsules group and the control group.
Conclusion: Jiangu capsules can decrease the degeneration of joint cartilage and synovia and the synovitis. Its mechanism is related to reduce the expression of IL-1βand to adjust the levels of MMP-1,MMP-3 and TIMP-1.
Objective: To study epidemiology and pathogenesis of osteoarthritis(OA) in TCM, and to study the effect of Jiangu capsules on pathology of cartilage and synovia of OA on experimental rabbits.
Methods: Make the OA models by injecting papain to the knees of experimental rabbits. Select Glucosamine Sulfate Capsules as the control group. Observe the effection of histology of joint cartilage and synovia, and the levels of matrix metalloproteinases(MMP)-1,3, tissue inhibitor sofmatrix metalloproteinases (TIMP) -1, interleukin(IL)-1βin cartilage and synovia.
Results: The histology changes of cartilage and synovia were lighter in Jiangu capsules group than that in model group (p<0.01). The levels of MMP-1,MMP-3, IL-1βin cartilage and synovia were decrease and level of TIMP-1 was increase. It showed significant different in Jiangu capsule group and the model group( p<0.01 or p<0.05).The level of IL-1βshowed significant different (p<0.05) and others showed insignificant different (p>0.05) in Jiangu capsules group and the control group.
Conclusion: Jiangu capsules can decrease the degeneration of joint cartilage and synovia and the synovitis. Its mechanism is related to reduce the expression of IL-1βand to adjust the levels of MMP-1,MMP-3 and TIMP-1.
引文
[1] 曾庆馀.症状性 OA 临床和流行病学探讨 中华内科杂志,1995;34(2):88.
[2] Yelin E. The economics of osteoarthritis.In:Brandt K, Doherty M,Lohmander LS,eds. Osteoarthrits,New York: Oxford University Press;1998;23-30.
[3] Felson DT .ZhangY. AN update on the epidemiology of knee and hip osteoarthritis with a view to prevention.Arthritis Rheum ,1984,41:1343- 1355.
[4] Ala-kokkol,Baldwin CT ,Moskowita RW,etal. Singal base mutation in the type Ⅱ procollaqen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia.ProcnatlAcadSci Lesa,1990;87:6565-6568.
[5] Bleasel JF etal. J Rhoumatol,1996,239(9):1594-1598.
[6] Radin EL.Mechanical aspects of osteoarthritis. Bull Rheum Dis ,1976;26:862-865.
[7] DequekerJ,Boonen S ,Acrssens J ,etal. In verse relationship osteoart- hritis-osteoporosis:What is evidence? Whte are the consequences Br J Rheumatol,1996;35:813-820.
[8] McAlindon TE.Jacques P,Zhang Y. etal. Do antioxidant micronutrients protect against the develepment an progression of knee osteoarthritis? Artbritis Rhenm, 1996;39:648-656.
[9] Halt DJ , et al.The relationship of obesity,fat distribution and osteoarthritis in women in the general population:The Chingford Study.J Rheumotol 1993,20(2):331 .
[10] Cooke TD: JRheumatol,10(Suppl9):55,1983.
[11] Alsalameh S,Jahn B,Krause A,et al.J Rheumatol,1991;18(3):414-421
[12] 八木国夫.临床病理, 1981.3:211.
[13] 解志杰,许建中.关节软骨的结构和代谢与年龄相关的变化.中华老年医学杂志,2000;19(15):394.
[14] 邓廉夫,柴本甫, 杨庆铭. 骨关节炎滑膜细胞分泌肿瘤坏死因子的生物学特征研究.中华骨科杂志,1999;19(12):726-729.
[15] Lotz M,GuernePA.J Biol Chem,1991;266:2017-2020.
[16] 娄思权.骨关节炎的病理与发病因素.中华骨伤科杂志,1996;16(1):56-59.
[17] KitohY,KatsuvamakiT,TanakaH,etal.Effect of SL-1010 (Sodium hyaluronate with high moleculer weight)on experimental osteoarthritis induced by intro-articularly,applied papain in rabbits.Folia pharmacol japon 1992;100:67.
[18] HenryJ,Mankin,Howarddorfman,etal.Biochemical and metabolic abnormal- ities in articular cartilage from osteoarthritic humanhips. Jbone Joint Surg(Am) 1971;53(3):523.
[19] Takahashi K,Goomer RS,Harwood F ,etal. The effects of hyaluronan on matrix metalloproteinase-3(MMP-3) ,interleukin-1 beta( IL-1 beta) ,and tissue inhibitor of metalloproteinase-1(TIMP-1)gene ex-pression during the development of osteoarthritis[ J].Osteoarthritis Cartilage, 1999; 7(2):182-190.
[20] LargoR,Alvarez-SoriaMA,Diez-OrtegoI,etal.Glu-cosam ine inhibits IL-1β-induced Nf-kappaB activation in human osteoarthritic hondrocytes[J]. Osteoarthritis Cartiloge,2003;11(4):290—298.
[21] 何耀华,翁习生,邱贵兴.白细胞介素 1β、肿瘤坏死因子α在膝关节原发性骨关节病发病中的作用.中华骨科杂志,1999;19(5):281-284.
[22]YoshiharaY,ObataK,Fujimoton,etal.Serumand synovial fluid level sofmatrix metalo proteinases,tissue inhibitor of metallo proteinases in patients with osteoarthritis 1Arthritis Rheum.1995;38:969-975.
[23] Yaron M,Shirazi I,Yaron I . Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures[J]. Osteoarthritis Cartilage ,1999;7(3) :272 一 280.
[24] Gouze JN,Bordji K,Gulberti S ,et al. lnterleukin-1 beta down-regulatesthe expression of glucuronosyl transferase1 ,a key enzyme priming glycosaminoglycan biosynthesis:influence of glucosamine on interleukinl beta mediated effects in rat chondrocytes[J]arthritis Rheum,2001;44(2),351～360.
[25] MartinG,BogdanowiczP,DomagalaF,etal.Rheinin-hibits interleukin-1 β-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1 in chondrocytes cultured in hypoxia:apotentialmechanismfor its disease-modifying effecting osteoarthritis[J].In-flammation,2003 ; 27(4):233～246.
[26] AhmedS,RahmanA,HasnainA,etal.Greenteapolyphenol epigallocatechin-3- gallate inhibits the IL-1-inducedactivityande - xpressionofcyc looxygenase-2andnitricox-idesynthase-2inhumanchondrocytes[J].Free Radic Biol Med,2002;33(8):1097—1105.
[27] 樊粤光,黄永明,曾意荣等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用.中国中医骨伤科杂志,2001;11(6):4-6.
[28] 罗佩强.土鳖虫促进骨折的实验研究[J].中国骨伤,1992;5(6):6.
[29] Wand, L, Ahnqvist KF, Veys EM,et al. Control of extranellular matrix homeostasis of normal cartilac byautoerinc pathway Validation of melahnlism in flow evtometrv as a tool to study chondrocyte metabolism in vitro.steoarthritis Cartilage,2002; 10( 3):188- 198.
[30] 王毅,邢国胜. IL-1β诱导软骨细胞培养金属蛋白酶/金属蛋白酶抑制剂水平及药物对其影响.中华风湿病学杂志,2003;12(7):718-721.
[31] 邹丹,全宏勋,胡群员.牛膝精对辐射小鼠造血干细胞增殖与分化的影响. 四川中医,2003;21(7):16-17.
[32] 高晓燕,王大为,李发美等.牛膝提取物对成骨样细胞增殖的作用.沈阳药科大学学报,2000;17(3) :210-213.
[33] 孙奋勇, 潘秋辉,洪岸.牛膝促进成骨细胞增殖的作用与机理研究. 中药材,2004;27(4):264-266.
[34] 赵湘洪,陈宝兴,丁继华,等.骨碎补对实验性骨性关节炎的治疗作用.中药材,2004;27(4):264-266 .
[35] 丁继华,赵湘洪,陈宝兴,等.补肾药治疗骨关节病的实验研究.中国中医骨伤科杂志,1989;5(3):3.
[36] Kurvliszvn M oskal A.Comparison of blood and synovial fluid lym phocyte subsets in rheumatoid arthritis and osteoarthritis[J] Clin Rheumatol,1995;14(1):43-50.
[37] 汪青春,石印玉,沈培芝等,中药对膝骨关节炎小鼠关节软骨 IL-1、iNOS 基因表达的影响.山西医药杂志,1999;28(5):381-383.
[38] 谢雁鸣,鞠大宏,赵晋宁等.骨碎补黄酮对去卵巢大鼠骨密度和细胞因子 IL-6、IL-4、TNFα水平的影响.中国中药杂志,2004;29(4):343-346.
[1] Patterson BC,Sang QA.J Biol Chem,1997;272(46):28823.
[2] Denis LT,Verweij J. Inv New Drugs,1997;15:175-185.
[3] Baker AH,Zaltsman AB,George SJ,etal .J CLin Invest,1998;101(6):1478-1487.
[4] Dahlberg L, Billinghurst R,Manner P,etal.[J].Arthritis Rheum,2000;43(3):673-682.
[5] Freemont AJ,Byers RJ,Taiwo YO,etal.[J].Ann Rheum Dis,1999;58(6):357- 365.
[6] WU CW,Tchetina EV,Mwale F, et al. Proteolysis involving matrix,metalloroteinase 13(collagenase-3) is required for chondrocyte differentiation that is associated with matrix mineralization. J Bone Miner Res, 2002;17(4):639- 651.
[7] Wand, L, Ahnqvist KF, Veys EM,et al. Control of extranellular matrix homeostasis of normal cartilac byautoerinc pathway Validation of melahnlism in flow evtometrv as a tool to study chondrocyte metabolism in vitro.steoarthritis Cartilage,2002;10( 3):188- 198.
[8] Mehraban F, Lark MV, Ahmed FN,etal.[J]. Osteoarthritis Cartilage,1998;6(4):286-294.
[9] 王毅,邢国胜. IL-1β诱导软骨细胞培养金属蛋白酶/金属蛋白酶抑制剂水平及药物对其影响. 中华风湿病学杂志,2003;12(7):718-721.
[10] Clegg PD,Carter SD.[J].Equine Vet J,1999;31(4):324-330.
[11] 管剑龙, 韩星海,施桂英等. 细胞因子和药物对软骨细胞和滑膜细胞金属蛋白酶活性的调节. 第二军医大学学报. 2000;21(9):961-864.
[12] Stronnin AY,Collier I,Bannikov G et al.J Biol Chem,1995;270:5331- 5338.
[13] Yamanaka H,Makino K,TakizawaM,et al.ab Invest, 2000; 80( 5):677-686.
[14] PaP T,Shineyama Y, Kuchen S.etal. Am College Rheuma, 2000;43( 6):1226- 1232.
[15] Okada Y,Sinmei M,Tanaka O,et al. Localization of matrixmet all oproteinase3(stromelysin) in osteoarthritic cartilage and synvium.Lab Invest, 1992;66:680～691.
[16] Imai K.Matrix metalloproteinase-7 from human rectal carcinoma cells: Activation of the precursor,interaction with othermatrix metalloprot- einases and enzymi cproperties. J BiolChem,1995; 270:6691～6699.
[17] 刘谟震,汤欣,吕德成. MMP-12 在类风湿关节炎中和骨性关节炎中的研究. 医师进修杂志,2004; 27( 12):23-24.
[18] Zafarullah M, Pelletier JP, Cloutier JM, et al. Elevated metal- oproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia.J Rheumatol,1993;20:693-697.
[19] Manicourt DH, Fujimoto N, Obata K, et al. Serum levels of collagenase, stromelysin-1, andTIMP 一 1. Age-and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum, 1994;37:1774-1783.
[20] Ishiguro N, Ito T, Ito H, et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum, 1999;42:129-136.
[21] 郑毅,陆江阳,孙笑非等.骨性关节炎患者滑膜和关节软骨中金属蛋白酶组织抑制物-1 的研究. 天津医药.2001;29(09):529-531.
[22] Naito K,Takahashi M,Kuahida K,etal.[J]. Rheumatology(Oxford),1999;38(6):510-515.
[23] YoshiharaY,ObataK,FujimotoN,etal.Serum and synovial fluid levels of matrix metalloproteinases,tissue inhibitor of metalloproteinases in patients with osteoarthritis.Arthritis Rheum.1995;38:969-975.
[24] Philippe E, Van den Steen, Paul Proost, et al. Neutrophil nelatinase B potentiates interleukin-8 tenfold by aminoterurinal processing, whereas it denrades CTAP-III, PF-4, and GRO-α and RANTTES and MCP-2intact[J]. Blood, 2000;96(8):2673-2681.
[25] Uwe Schonbeck,Francois Mach,Peter Libby.Generation of biologically active IL-1 by matrix metalloproteinases:A novel caspase-l-independent pathway of IL-lp processing[J].J lmmunol,1998;161(7):3340-3346.
[26] Im HJ, Pacione C,Chuhinskaya S, et al. Inhihitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment-and interleukin-1 β-stimulated,matris metalloproteinase- βexpression in human chondrocytes[J].J Biol Chem,2003;278( 28): 25386-25394.
[27] Han I,Boyle DL,,Aupperle KR,et al.Jnn N-terminal Kinase in sheumatoidar- thritis.J Pharm Exp Therapeutics.1999;291:124-130.
[28] 赵庆华,亓建洪,孙巧玲,燕好军.白细胞介素 1 对骨性关节炎软骨细胞基质金属蛋白酶阻滞剂 1 基因表达的影响.中国临床康复,2004;8(20):4020-4023.
[29] 卫晓恩.骨性关节炎的遗传学因素,中国临床康复.2002;2003;6(1):8-9.
[30] 汪青春,石印玉,沈培芝等,中药对膝骨性关节炎小鼠关节软骨 IL-1、iNOS 基因表达的影响.山西医药杂志,1999;28(5):381-383.
[31] Yaron M,Shirazi I,Yaron I . Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures[J].Osteoarthritis Cartilage ,1999;7(3):272-280.
[32] Gouze JN,Bordji K,Gulberti S ,et al. lnterleukin-1 beta down-regulates the expression of glucuronosyl transferase1,a key enzyme priming glycosaminoglycan biosynthesis:influence of glucosamine on interleukinl beta mediated effects in rat chondrocytes[J]arthritis Rheum,2001 ;44(2) ,351～360.
[33] SpencerCM,WildeMI Drugs,1997,53(1):98-106.
[34] Moldvon F,Pelletter JP,Jolcoeur FC,et al.Osteoarthritis Cartilage, 2000,8(3):186-196.
[35] TamuraT, OhmoriK.JpnJ Pharmacol,2001;85(l):257～263 .
[36] Takahashi K,Goomer RS,Harwood F ,etal. The effects of hyaluronan on matrix metalloproteinase-3(MMP-3) ,interleukin-1 beta( IL-1 beta) ,and tissueinhibitor of metalloproteinase-1(TIMP-1)gene ex-pression during the development of osteoarthritis[ J].Osteoarthritis Cartilage, 1999;7(2):182-190.
[37] HarveyAK,HrubeyPS,ChandrasekharS.TGFB inhibition of interleukin1 activity involves down-regulation of IL1 receptors on chondrocytes? ExpCellRes,1991;195:376-385.
[38] Von-den-Hoff HW,de-KoningMH,van-KampenGP,etal.Transforming growth factor-beta stimulates retinoic acid-induced proteogly can depletion in intact articular cartilage.Arch Biochem Biophys,1994;313:241-247.
[39] Smith GN, Yu LP, Brandt KD, et al. Oral administration of doxycycline reduces cullagcnase and gelaLinasce activities in extracts of human osteoarthritic cartlage .J Rheumatol, 1998;25: 532-535.
[40] Altman RD, Dean DD,Mnniz OE, et al. Therapeutic treatment of canine osteoarthritis wilh glycosaminoglycan polysnlfnric acid ester Arthritis Rheum,1989;32:1300-1307.
[41] Smith GN Jr,Yu LP Jr,Brandt KD,etal.Oraladministration odoxycycline reduces collagenase and gelatinase activitiesin extract of human osteoarthritic cartilage.J Rheumatol,1998;25:532-535.
[42] Dean DD,Muniz OE, Rodriquez I,etal.Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan peptide as sociation complex (Rumalon).Arthritis Rheum,1991;34:304-313.
[43] Altman RD,Dean DD,Muniz OE,etal.Therapeutic treatment of canineoste oarthritis with glycosaminoglycan polysulfuricacidester.Arthritis Rheum,1989;32:1300-1307.
[44] Skotnicki JS,Zask A,Nelson FC,et al.[J].Ann NY Acad Sci,1999;878:61-72.
[45] Wojtowicz Praga SM,Dickson RB,Hawkins MJ,etal. Matrix metalloproteinase in hibitors.Invest New Drugs,1997;15:61-75.
[46] Liu YE,Wang M,Greene J,etal. Preparation and characterization of recombinant tissue inhibitor of metall oproteinase 4(TIMP24).J BiolChem,1997;272:20479-20483.
[1] 石印玉.养血软坚方治疗膝关节炎的临床报告[J].中国中医骨伤科,1994,2(4):33-35.
[2] 李同生,等.补肾健骨汤治疗骨性关节病的临床研究.中国中医骨伤科,1993;1(1):18-21.
[3] 沈霖,等.补肾健骨汤对膝关节骨性关节病患者氧自由基代谢的影响.中国骨伤,1996;9(4):8-12.
[4] 朱洪民,宁显明.黄芪桂枝五物胶囊治疗膝骨关节炎临床研究[J].福建中医药,2002;33(3):15-16.
[5] 陈炳坤.当归四逆汤加减治疗膝关节骨性关节炎 85 例疗效观察.中医正骨,1995; (7)5:30-33.
[6] 杜善颖.辨证治疗痹证 220 例疗效观察.中医函授通讯,1986;(5):762-765.
[7] 陈三才.200 例类风湿关节炎诱因调查.上海中医药杂志,1981;(7):29-33
[8] 严肃云.痹证 116 例的辨证施治.浙江中医杂志,1985;20(7):327-330.
[9] 苏纯玉.三痹汤加减治疗老年性风寒湿性关节痹.中国骨伤,1989;(4):40-44.
[10] 易宪文,方世源,孙树椿.寒湿痹发病机理的实验研究.中国骨伤,1989(4):9-13.
[11] 舒尚义.类风湿性关节炎分型辨证体会——附 90 例疗效分析.云南中医杂志,1984;(5):15-17.
[12] 朱正刚.疗骨丸治疗膝关节增生性关节炎 42 例临床观察.中医杂志,1992;33(11):38-40.
[13] 杜秀兰.增生消痛汤治疗增生性膝关节病 55 例.山东中医杂志,1994;13(1):14-16
[14] 李恒敏.软坚化瘀法治疗骨关节病[J].中医杂志,1995,36(3):147-149.
[15] 刘金陵,等.补肝汤加减治疗骨性膝关节炎 76 例.广西中医药,1995;18(2):10-12.
[16] 谢林,等.丹紫康膝冲剂对膝关节退行性骨关节病患者氧自由基代谢的影响.中国中医骨伤科杂志,1996;4(2):8-11.
[17] 陈广祯,李自沁,梁安民.从瘀血痰湿论治膝关节骨性关节炎 58 例[J].山东中医药大学学报,1995;22:30-31.
[18] 林俊宏.综合治疗膝关节骨性关节炎 62 例[J]长春中医学院学报,2002;18(l):29-30.
[19] 胡永东.补肾活血汤治疗增生性骨关节病 28 例[J]陕西中医,2002;23(9):805-806.
[20] 李斌.自拟化骨散治疗增生性膝关节炎 28 例[J]四川中医,2002;20(7):67-68.
[21] 陈本华.祛痹方治疗骨关节炎 35 例临床观察[J]福建中医药,2002;33(l):l3-14.
[22] 吕同杰.略谈增生性关节炎的中医药治疗.山东中医杂志,1984;(1):1-5.
[23] 江蓉星,汪亚强,王志洪.骨关节炎的中医治疗[J].成都中医药大学学报,2001;24(4):11-13.
[24] 陈庚红.新癀片与仙骨葆合用治疗中老年骨关节退行性变的临床观察.[J]中国中西医结合杂志,2002;22(8):586-589.
[25] 吴林生,金嫣丽. 中药及手法治疗膝关节骨性关节炎 121 例疗效分析[J]. 中医杂志,1993,13(12):742-744.
[26] 张建福.骨质增生病的中西医诊疗.北京:中国中医药出版社,1995:59.
[27] 刘洪旺.退行性膝关节骨性关节病的中医辨证施治[J].中国骨伤,1997,10(4):27-29.
[28] 王少山,张世华,邱红明,等.骨病中西医诊疗学.北京:中国中医药出版社,200;218:6-9.
[29] 宏树臣. 中医指针综合治疗膝关节骨性关节炎[J]. 中国骨伤,1998;(5). 19～20-22.
[30] 诸方受.增生性关节炎 22 例疗效观察.中国骨伤,1991;4(3):3-5.
[31] 赵勇.中国骨伤方药大全.北京:学苑出版社,1995 年。187-188.
[32] 单文龙,陈茹琴.独活寄生汤加减治疗骨关节炎 24 例.江苏中医,1993,14(3):11-13.
[33] 金毅.独活寄生汤治疗膝关节骨质增生 30 例.广西中医药,1990;(3):38-40.
[34] 杜见斌.益肝补肾通络法治疗骨性关节炎 96 例.山东中医杂志,1992;11(1):19-20.
[35] 陈星南,陈建良. 补气活血法治疗膝部骨关节炎的临床应用体会[J]. 光明中医,1998;(3). 48～50.
[36] 周有华,裴明秀,毛鹏等.中西医结合治疗膝关节骨性关节炎 75 例.广西中医药,1989;12,(4):13-15.
[37] 范明等.中医治疗膝关节增生性关节炎的临床体会.辽宁中医杂志,1984(12):22-24
[38] 王魁亮.骨痹汤治疗膝关节骨性关节炎 54 例临床观察,新疆中医药.1993;(2):27-29.
[39] 章煜铭.补肾壮筋汤治疗退行性骨关节病 183 例.浙江中医杂志,1992; 27(4): 174-176.
[40] 马素英.应用马氏骨刺丸治疗骨性关节炎 216 例.北京中医杂志,1993;3:49-52.
[41] 陈建鸿.中医中药治疗膝关节骨关节炎 54 例临床体会.中国中医骨伤科,1995;3(6):3611-3613.
[42] 刘德玉.李堪印教授治疗骨性关节炎临床经验.山西中医学院学报.1999;22(1):19-23.
[43] 许书亮,苏友新,林俊仁.骨炎汤治疗膝骨性关节炎 158 例临床研究[J].中国中医骨伤科杂志,2001;9(1):45-46.
[44] 崔连光.壮筋束骨丸治疗骨质增生腰腿痛 62 例.山东中医杂志,1992;11(6):23-25.
[45] 王承训.强骨散治疗颈椎增生 300 例.山东中医杂志,1995;14(7):305-307.
[46] 高学礼.加味苍柏汤治疗增生性关节炎 65 例.山东中医杂志,1991;10(1):22-24.
[47] 施杞.中国中医骨伤科百家方技精华.北京:中国中医出版社,1990;165:45.
[48] 邢峰.自制复方风湿康治疗骨关节炎 68 例临床观察.安徽中医临床杂志,1998;10,10(6):371-372.
[49] 王明武. 骨刺丸治疗骨质增生 133 例报告[J]. 中国中医骨伤科,1995;(1):65-67.
[50] 陈立忠,姬艳波,段瑛春. 自拟益肾强骨汤治疗膝关节骨性关节炎 72 例疗效观察[J]. 中医正骨,1997;(4):231-233.
[51] 陈泽文,喻友军.骨痹汤治疗膝关节骨性关节炎 82 例总结[J]. 湖南中医杂志,2002;(3):87-89.
[52] 孟庆莉,赵生文.补肾祛瘀法治疗骨关节炎 139 例。河南中医,2002;22(2):51-54.
[53] 蒋连泓.“关节消肿止痛冲剂”治疗各种关节炎 102 例疗效观察.天津中医,1992,(4):13-15.
[54] 王敖明,邱德华.石氏调中保元汤治疗老年性膝关节病[J].上海中医药杂志2001;(7):34-35.
[55] 吴永昕,肖泓,吴生元.补中桂枝汤治疗退行性骨关节病 83 例.四川中医,2002;20(2):63-64.
[56] 许建安.二藤汤治疗膝关节骨关节病经验介绍.中国中医骨伤科,1993;(1):34-35.
[57] 赵龙.健膝汤治疗膝关节骨质增生.中国骨伤.1996,9(2):47-49.
[58] 路则显.灵仙汤治疗膝关节骨性关节炎[J].四川中医,1996,14(7):47-50.
[59] 邓伟.养血祛风除湿治疗增生性膝关节炎 50 例[J].实用中医药杂志,1997;13(4):3-5.
[60] 杜天信,韩新峰,高书图.寒湿痹颗粒治疗寒湿痹阻型风湿病的临床观察。中医正骨,2002;14(3):10-12.
[61] 周联耀.中西医结合治疗老年性骨关节炎.中国骨伤,1995,8(5):27-29.
[62] 李强,李同生.健骨汤治疗骨性关节病临床及实验研究.中医正骨,1992,4(3):9-12.
[63] 严培军,孙玉明,周福贻. 从痰瘀水论治膝关节骨性关节炎 176 例[J]. 南京中医药大学学报(自然科学版),2000;(4):249-251.
[64] 雷波,刘定安. 从瘀血痰湿论治膝关节骨关节病 48 例临床观察[J]. 湖南中医杂志,1999;15(2):12-13.
[65] 宋绍亮.张鸣鹤主任医师治疗关节病的经验.山东中医杂志,1991,10(3):44-47.
[66] 宋绍亮.骨疣初探.山东中医杂志,1993;12(3):3-5.
[67] 贺建平.制马钱子散治疗骨质增生及风湿病 108 例.江西中医药,1994,25(4):38-39.
[68] 李汉俊.蚂蚁风湿消治疗腰椎骨关节炎 76 例[J].中国中医药信息杂志,1996;(12):54-56.
[69] 周翠英.蠲水汤治疗膝关节退行性病变合并滑膜炎 42 例. 山东中医杂志,1991;10(3):35-36.
[70] 韩新峰,杜天信,李无阴.湿热痹颗粒治疗湿热痹阻型风湿病的临床观察. 中医正骨,2002;14(4):9-11.
[71] 杨久山,张维文.通痹汤治疗膝骨性关节炎伴关节积液 24 例[J].山东中医药大学学报,2000;24(6):446-447.
[72] 高文香,刘元禄,李永生,等.补肾法防治兔膝关节骨性关节炎的病理形态学观察[J].中医正骨,1999;11(11):13-15.
[73] 高文香,任汉阳,周颖,刘元禄.补肾法与活血法治疗兔膝骨关节炎的病理形态学对比研究.中医正骨,2000;12(6):5-8.
[74] 董建勇,赵晓薇,李立.附桂关节汤防治骨性关节炎作用的形态学观察[J].甘肃中医学院学报,1997,14(1):27-30.
[75] 沈培芝.强筋方治疗骨性关节炎的组织病理学观察研究[J].中国中医骨伤科,1995,3(l):1-3.
[76] 任峰.益气养血通络法(治血痹法)对小鼠骨关节病的实验研究.上海中医药杂志,1994,(7):41-42.
[77] 汪青春,沈培芝,徐宇,石印玉.不同方药治疗膝骨关节炎的组织形态学对比研究.中国中医骨伤科杂志,1998;6(2):1-3.
[78] 王羽丰,许学孟,邓晋丰.补肾活血胶囊影响兔膝关节退变性疾病组织形态学的实验研究.中国中医骨伤科,1999;7(4):9-10.
[79] 王耶,刘建宇,宋艳,等. 丹参和透明质酸钠注射液对骨关节炎治疗作用的实验研究[J].中国生化药物杂志, 1998; 19 (3) :248-251.
[80] 江伟达,郑效文,郑清波,等.中药关节Ⅲ号方治疗家兔膝骨关节炎的实验研究[J].中国中医骨伤科,1994,2(1):1-3.
[81] 毛小兵,邹季.风湿骨痛药酒药槌外治法防治关节软骨退变的实验研究[J].中医正骨,2002;15(4):220-221.
[82] 晏雪生,彭亚琴,明安萍.川芎嗪注射液对体外培养软骨影响的实验研究[J].中国中医骨伤科杂志,2002;10(1):15-17.
[83] 冯伟,石印玉,沈培芝,等.中药对软骨细胞代谢的影响[J].中国中医骨伤杂志,2000;8(2):9-12.
[84] 王国文,潘海东,曲波.参脉注射液对骨关节炎模型动物关节软骨胶原含量的影响[J].中国中医骨伤杂志,2001;9(2):14-16.
[85] 李承军,吴志奎,陈玉英.补肾壮骨药对老年大鼠软骨代谢作用的研究.中药药理与临床,1995,11(1)34-36.
[86] 岳珍,王嘉夫,吕红斌.行气消肿类中药对体外培养的软骨细胞代谢的影响[J].中国运动学杂志,1996,16(1):34-37.
[87] 王济伟,史炜镔,杜宁,等.手法治疗实验性膝骨关节炎的血流动力学研究[J].中国骨伤,1997,10(6):13-15.
[88] 潘海东,曲波,王耶.参麦注射液对骨关节炎动物模型血液中白细胞介素 1 水平的影响[J].中国中医骨伤科杂志,2000;8(1):17-18.
[89] 王拥军,施杞,石印玉等.芪麝颈康丸对颈椎间盘内 IL-12、IL-6、TNFα含量的影响.中国中医骨伤科杂志,2000;8(1):23-26.
[90] 曹月龙,郑昱新,石印玉.养血软坚胶囊治疗膝骨关节炎疗效及安全性评价的随机对照试验[J].中国药物与临床,2004;4(6):423-427.
[91] 马建兵,沙浩渡,李向阳,陈明凡,王晓安. 兔实验性膝骨性关节炎的组织病理学及发病机理[J]. 中国矫形外科杂志,2001;(1):43-45.
[92] 汪青春,董蕙芳,沈培芝,等.中药对膝骨关节炎黑鼠血清 SOD、HA、NO 水平的影响[J].中医正骨,1999;11(5):6-8.
[93] 周尊谦.丹紫康膝冲剂治疗膝关节退行性骨关节病临床观察。中国骨伤,1999;12(12):49-51.
[94] 王毅,邢国胜,于顺禄等。IL-1β诱导软骨细胞培养金属蛋白酶/金属蛋白酶抑制剂水平及药物对其影响.中华风湿病学杂志,2003;7(12):718-721.
[95] 张磊,胡阿威,张功礼等.痹康灵对骨关节炎治疗作用的实验研究,中医正骨,2004;16(7)4-6.
[96] 黄枫,唐勇,郑晓辉.补肾强膝方对绝经后妇女膝骨性关节炎的影响[J].中医正骨,2002;14(4):12-15.
[97] 万荣,杨庆铭,邓廉夫.黑虎丹治疗兔骨关节炎的实验研究[J].中国骨伤,2001;14(2):85-87.
[98] 魏玉玲,刘营杰,梁克玉.消痹灵治疗骨性关节炎的机制探讨.现代康复,2001;5(4):66-67.
[99] 沈霖,沈耀,杨述华.丹参注射液对维甲酸诱导的软骨细胞凋亡的影响[J].中国中医骨伤科杂志,2002;10(5):1-4.
[2] Yelin E. The economics of osteoarthritis.In:Brandt K, Doherty M,Lohmander LS,eds. Osteoarthrits,New York: Oxford University Press;1998;23-30.
[3] Felson DT .ZhangY. AN update on the epidemiology of knee and hip osteoarthritis with a view to prevention.Arthritis Rheum ,1984,41:1343- 1355.
[4] Ala-kokkol,Baldwin CT ,Moskowita RW,etal. Singal base mutation in the type Ⅱ procollaqen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia.ProcnatlAcadSci Lesa,1990;87:6565-6568.
[5] Bleasel JF etal. J Rhoumatol,1996,239(9):1594-1598.
[6] Radin EL.Mechanical aspects of osteoarthritis. Bull Rheum Dis ,1976;26:862-865.
[7] DequekerJ,Boonen S ,Acrssens J ,etal. In verse relationship osteoart- hritis-osteoporosis:What is evidence? Whte are the consequences Br J Rheumatol,1996;35:813-820.
[8] McAlindon TE.Jacques P,Zhang Y. etal. Do antioxidant micronutrients protect against the develepment an progression of knee osteoarthritis? Artbritis Rhenm, 1996;39:648-656.
[9] Halt DJ , et al.The relationship of obesity,fat distribution and osteoarthritis in women in the general population:The Chingford Study.J Rheumotol 1993,20(2):331 .
[10] Cooke TD: JRheumatol,10(Suppl9):55,1983.
[11] Alsalameh S,Jahn B,Krause A,et al.J Rheumatol,1991;18(3):414-421
[12] 八木国夫.临床病理, 1981.3:211.
[13] 解志杰,许建中.关节软骨的结构和代谢与年龄相关的变化.中华老年医学杂志,2000;19(15):394.
[14] 邓廉夫,柴本甫, 杨庆铭. 骨关节炎滑膜细胞分泌肿瘤坏死因子的生物学特征研究.中华骨科杂志,1999;19(12):726-729.
[15] Lotz M,GuernePA.J Biol Chem,1991;266:2017-2020.
[16] 娄思权.骨关节炎的病理与发病因素.中华骨伤科杂志,1996;16(1):56-59.
[17] KitohY,KatsuvamakiT,TanakaH,etal.Effect of SL-1010 (Sodium hyaluronate with high moleculer weight)on experimental osteoarthritis induced by intro-articularly,applied papain in rabbits.Folia pharmacol japon 1992;100:67.
[18] HenryJ,Mankin,Howarddorfman,etal.Biochemical and metabolic abnormal- ities in articular cartilage from osteoarthritic humanhips. Jbone Joint Surg(Am) 1971;53(3):523.
[19] Takahashi K,Goomer RS,Harwood F ,etal. The effects of hyaluronan on matrix metalloproteinase-3(MMP-3) ,interleukin-1 beta( IL-1 beta) ,and tissue inhibitor of metalloproteinase-1(TIMP-1)gene ex-pression during the development of osteoarthritis[ J].Osteoarthritis Cartilage, 1999; 7(2):182-190.
[20] LargoR,Alvarez-SoriaMA,Diez-OrtegoI,etal.Glu-cosam ine inhibits IL-1β-induced Nf-kappaB activation in human osteoarthritic hondrocytes[J]. Osteoarthritis Cartiloge,2003;11(4):290—298.
[21] 何耀华,翁习生,邱贵兴.白细胞介素 1β、肿瘤坏死因子α在膝关节原发性骨关节病发病中的作用.中华骨科杂志,1999;19(5):281-284.
[22]YoshiharaY,ObataK,Fujimoton,etal.Serumand synovial fluid level sofmatrix metalo proteinases,tissue inhibitor of metallo proteinases in patients with osteoarthritis 1Arthritis Rheum.1995;38:969-975.
[23] Yaron M,Shirazi I,Yaron I . Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures[J]. Osteoarthritis Cartilage ,1999;7(3) :272 一 280.
[24] Gouze JN,Bordji K,Gulberti S ,et al. lnterleukin-1 beta down-regulatesthe expression of glucuronosyl transferase1 ,a key enzyme priming glycosaminoglycan biosynthesis:influence of glucosamine on interleukinl beta mediated effects in rat chondrocytes[J]arthritis Rheum,2001;44(2),351～360.
[25] MartinG,BogdanowiczP,DomagalaF,etal.Rheinin-hibits interleukin-1 β-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1 in chondrocytes cultured in hypoxia:apotentialmechanismfor its disease-modifying effecting osteoarthritis[J].In-flammation,2003 ; 27(4):233～246.
[26] AhmedS,RahmanA,HasnainA,etal.Greenteapolyphenol epigallocatechin-3- gallate inhibits the IL-1-inducedactivityande - xpressionofcyc looxygenase-2andnitricox-idesynthase-2inhumanchondrocytes[J].Free Radic Biol Med,2002;33(8):1097—1105.
[27] 樊粤光,黄永明,曾意荣等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用.中国中医骨伤科杂志,2001;11(6):4-6.
[28] 罗佩强.土鳖虫促进骨折的实验研究[J].中国骨伤,1992;5(6):6.
[29] Wand, L, Ahnqvist KF, Veys EM,et al. Control of extranellular matrix homeostasis of normal cartilac byautoerinc pathway Validation of melahnlism in flow evtometrv as a tool to study chondrocyte metabolism in vitro.steoarthritis Cartilage,2002; 10( 3):188- 198.
[30] 王毅,邢国胜. IL-1β诱导软骨细胞培养金属蛋白酶/金属蛋白酶抑制剂水平及药物对其影响.中华风湿病学杂志,2003;12(7):718-721.
[31] 邹丹,全宏勋,胡群员.牛膝精对辐射小鼠造血干细胞增殖与分化的影响. 四川中医,2003;21(7):16-17.
[32] 高晓燕,王大为,李发美等.牛膝提取物对成骨样细胞增殖的作用.沈阳药科大学学报,2000;17(3) :210-213.
[33] 孙奋勇, 潘秋辉,洪岸.牛膝促进成骨细胞增殖的作用与机理研究. 中药材,2004;27(4):264-266.
[34] 赵湘洪,陈宝兴,丁继华,等.骨碎补对实验性骨性关节炎的治疗作用.中药材,2004;27(4):264-266 .
[35] 丁继华,赵湘洪,陈宝兴,等.补肾药治疗骨关节病的实验研究.中国中医骨伤科杂志,1989;5(3):3.
[36] Kurvliszvn M oskal A.Comparison of blood and synovial fluid lym phocyte subsets in rheumatoid arthritis and osteoarthritis[J] Clin Rheumatol,1995;14(1):43-50.
[37] 汪青春,石印玉,沈培芝等,中药对膝骨关节炎小鼠关节软骨 IL-1、iNOS 基因表达的影响.山西医药杂志,1999;28(5):381-383.
[38] 谢雁鸣,鞠大宏,赵晋宁等.骨碎补黄酮对去卵巢大鼠骨密度和细胞因子 IL-6、IL-4、TNFα水平的影响.中国中药杂志,2004;29(4):343-346.
[1] Patterson BC,Sang QA.J Biol Chem,1997;272(46):28823.
[2] Denis LT,Verweij J. Inv New Drugs,1997;15:175-185.
[3] Baker AH,Zaltsman AB,George SJ,etal .J CLin Invest,1998;101(6):1478-1487.
[4] Dahlberg L, Billinghurst R,Manner P,etal.[J].Arthritis Rheum,2000;43(3):673-682.
[5] Freemont AJ,Byers RJ,Taiwo YO,etal.[J].Ann Rheum Dis,1999;58(6):357- 365.
[6] WU CW,Tchetina EV,Mwale F, et al. Proteolysis involving matrix,metalloroteinase 13(collagenase-3) is required for chondrocyte differentiation that is associated with matrix mineralization. J Bone Miner Res, 2002;17(4):639- 651.
[7] Wand, L, Ahnqvist KF, Veys EM,et al. Control of extranellular matrix homeostasis of normal cartilac byautoerinc pathway Validation of melahnlism in flow evtometrv as a tool to study chondrocyte metabolism in vitro.steoarthritis Cartilage,2002;10( 3):188- 198.
[8] Mehraban F, Lark MV, Ahmed FN,etal.[J]. Osteoarthritis Cartilage,1998;6(4):286-294.
[9] 王毅,邢国胜. IL-1β诱导软骨细胞培养金属蛋白酶/金属蛋白酶抑制剂水平及药物对其影响. 中华风湿病学杂志,2003;12(7):718-721.
[10] Clegg PD,Carter SD.[J].Equine Vet J,1999;31(4):324-330.
[11] 管剑龙, 韩星海,施桂英等. 细胞因子和药物对软骨细胞和滑膜细胞金属蛋白酶活性的调节. 第二军医大学学报. 2000;21(9):961-864.
[12] Stronnin AY,Collier I,Bannikov G et al.J Biol Chem,1995;270:5331- 5338.
[13] Yamanaka H,Makino K,TakizawaM,et al.ab Invest, 2000; 80( 5):677-686.
[14] PaP T,Shineyama Y, Kuchen S.etal. Am College Rheuma, 2000;43( 6):1226- 1232.
[15] Okada Y,Sinmei M,Tanaka O,et al. Localization of matrixmet all oproteinase3(stromelysin) in osteoarthritic cartilage and synvium.Lab Invest, 1992;66:680～691.
[16] Imai K.Matrix metalloproteinase-7 from human rectal carcinoma cells: Activation of the precursor,interaction with othermatrix metalloprot- einases and enzymi cproperties. J BiolChem,1995; 270:6691～6699.
[17] 刘谟震,汤欣,吕德成. MMP-12 在类风湿关节炎中和骨性关节炎中的研究. 医师进修杂志,2004; 27( 12):23-24.
[18] Zafarullah M, Pelletier JP, Cloutier JM, et al. Elevated metal- oproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia.J Rheumatol,1993;20:693-697.
[19] Manicourt DH, Fujimoto N, Obata K, et al. Serum levels of collagenase, stromelysin-1, andTIMP 一 1. Age-and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum, 1994;37:1774-1783.
[20] Ishiguro N, Ito T, Ito H, et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum, 1999;42:129-136.
[21] 郑毅,陆江阳,孙笑非等.骨性关节炎患者滑膜和关节软骨中金属蛋白酶组织抑制物-1 的研究. 天津医药.2001;29(09):529-531.
[22] Naito K,Takahashi M,Kuahida K,etal.[J]. Rheumatology(Oxford),1999;38(6):510-515.
[23] YoshiharaY,ObataK,FujimotoN,etal.Serum and synovial fluid levels of matrix metalloproteinases,tissue inhibitor of metalloproteinases in patients with osteoarthritis.Arthritis Rheum.1995;38:969-975.
[24] Philippe E, Van den Steen, Paul Proost, et al. Neutrophil nelatinase B potentiates interleukin-8 tenfold by aminoterurinal processing, whereas it denrades CTAP-III, PF-4, and GRO-α and RANTTES and MCP-2intact[J]. Blood, 2000;96(8):2673-2681.
[25] Uwe Schonbeck,Francois Mach,Peter Libby.Generation of biologically active IL-1 by matrix metalloproteinases:A novel caspase-l-independent pathway of IL-lp processing[J].J lmmunol,1998;161(7):3340-3346.
[26] Im HJ, Pacione C,Chuhinskaya S, et al. Inhihitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment-and interleukin-1 β-stimulated,matris metalloproteinase- βexpression in human chondrocytes[J].J Biol Chem,2003;278( 28): 25386-25394.
[27] Han I,Boyle DL,,Aupperle KR,et al.Jnn N-terminal Kinase in sheumatoidar- thritis.J Pharm Exp Therapeutics.1999;291:124-130.
[28] 赵庆华,亓建洪,孙巧玲,燕好军.白细胞介素 1 对骨性关节炎软骨细胞基质金属蛋白酶阻滞剂 1 基因表达的影响.中国临床康复,2004;8(20):4020-4023.
[29] 卫晓恩.骨性关节炎的遗传学因素,中国临床康复.2002;2003;6(1):8-9.
[30] 汪青春,石印玉,沈培芝等,中药对膝骨性关节炎小鼠关节软骨 IL-1、iNOS 基因表达的影响.山西医药杂志,1999;28(5):381-383.
[31] Yaron M,Shirazi I,Yaron I . Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures[J].Osteoarthritis Cartilage ,1999;7(3):272-280.
[32] Gouze JN,Bordji K,Gulberti S ,et al. lnterleukin-1 beta down-regulates the expression of glucuronosyl transferase1,a key enzyme priming glycosaminoglycan biosynthesis:influence of glucosamine on interleukinl beta mediated effects in rat chondrocytes[J]arthritis Rheum,2001 ;44(2) ,351～360.
[33] SpencerCM,WildeMI Drugs,1997,53(1):98-106.
[34] Moldvon F,Pelletter JP,Jolcoeur FC,et al.Osteoarthritis Cartilage, 2000,8(3):186-196.
[35] TamuraT, OhmoriK.JpnJ Pharmacol,2001;85(l):257～263 .
[36] Takahashi K,Goomer RS,Harwood F ,etal. The effects of hyaluronan on matrix metalloproteinase-3(MMP-3) ,interleukin-1 beta( IL-1 beta) ,and tissueinhibitor of metalloproteinase-1(TIMP-1)gene ex-pression during the development of osteoarthritis[ J].Osteoarthritis Cartilage, 1999;7(2):182-190.
[37] HarveyAK,HrubeyPS,ChandrasekharS.TGFB inhibition of interleukin1 activity involves down-regulation of IL1 receptors on chondrocytes? ExpCellRes,1991;195:376-385.
[38] Von-den-Hoff HW,de-KoningMH,van-KampenGP,etal.Transforming growth factor-beta stimulates retinoic acid-induced proteogly can depletion in intact articular cartilage.Arch Biochem Biophys,1994;313:241-247.
[39] Smith GN, Yu LP, Brandt KD, et al. Oral administration of doxycycline reduces cullagcnase and gelaLinasce activities in extracts of human osteoarthritic cartlage .J Rheumatol, 1998;25: 532-535.
[40] Altman RD, Dean DD,Mnniz OE, et al. Therapeutic treatment of canine osteoarthritis wilh glycosaminoglycan polysnlfnric acid ester Arthritis Rheum,1989;32:1300-1307.
[41] Smith GN Jr,Yu LP Jr,Brandt KD,etal.Oraladministration odoxycycline reduces collagenase and gelatinase activitiesin extract of human osteoarthritic cartilage.J Rheumatol,1998;25:532-535.
[42] Dean DD,Muniz OE, Rodriquez I,etal.Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan peptide as sociation complex (Rumalon).Arthritis Rheum,1991;34:304-313.
[43] Altman RD,Dean DD,Muniz OE,etal.Therapeutic treatment of canineoste oarthritis with glycosaminoglycan polysulfuricacidester.Arthritis Rheum,1989;32:1300-1307.
[44] Skotnicki JS,Zask A,Nelson FC,et al.[J].Ann NY Acad Sci,1999;878:61-72.
[45] Wojtowicz Praga SM,Dickson RB,Hawkins MJ,etal. Matrix metalloproteinase in hibitors.Invest New Drugs,1997;15:61-75.
[46] Liu YE,Wang M,Greene J,etal. Preparation and characterization of recombinant tissue inhibitor of metall oproteinase 4(TIMP24).J BiolChem,1997;272:20479-20483.
[1] 石印玉.养血软坚方治疗膝关节炎的临床报告[J].中国中医骨伤科,1994,2(4):33-35.
[2] 李同生,等.补肾健骨汤治疗骨性关节病的临床研究.中国中医骨伤科,1993;1(1):18-21.
[3] 沈霖,等.补肾健骨汤对膝关节骨性关节病患者氧自由基代谢的影响.中国骨伤,1996;9(4):8-12.
[4] 朱洪民,宁显明.黄芪桂枝五物胶囊治疗膝骨关节炎临床研究[J].福建中医药,2002;33(3):15-16.
[5] 陈炳坤.当归四逆汤加减治疗膝关节骨性关节炎 85 例疗效观察.中医正骨,1995; (7)5:30-33.
[6] 杜善颖.辨证治疗痹证 220 例疗效观察.中医函授通讯,1986;(5):762-765.
[7] 陈三才.200 例类风湿关节炎诱因调查.上海中医药杂志,1981;(7):29-33
[8] 严肃云.痹证 116 例的辨证施治.浙江中医杂志,1985;20(7):327-330.
[9] 苏纯玉.三痹汤加减治疗老年性风寒湿性关节痹.中国骨伤,1989;(4):40-44.
[10] 易宪文,方世源,孙树椿.寒湿痹发病机理的实验研究.中国骨伤,1989(4):9-13.
[11] 舒尚义.类风湿性关节炎分型辨证体会——附 90 例疗效分析.云南中医杂志,1984;(5):15-17.
[12] 朱正刚.疗骨丸治疗膝关节增生性关节炎 42 例临床观察.中医杂志,1992;33(11):38-40.
[13] 杜秀兰.增生消痛汤治疗增生性膝关节病 55 例.山东中医杂志,1994;13(1):14-16
[14] 李恒敏.软坚化瘀法治疗骨关节病[J].中医杂志,1995,36(3):147-149.
[15] 刘金陵,等.补肝汤加减治疗骨性膝关节炎 76 例.广西中医药,1995;18(2):10-12.
[16] 谢林,等.丹紫康膝冲剂对膝关节退行性骨关节病患者氧自由基代谢的影响.中国中医骨伤科杂志,1996;4(2):8-11.
[17] 陈广祯,李自沁,梁安民.从瘀血痰湿论治膝关节骨性关节炎 58 例[J].山东中医药大学学报,1995;22:30-31.
[18] 林俊宏.综合治疗膝关节骨性关节炎 62 例[J]长春中医学院学报,2002;18(l):29-30.
[19] 胡永东.补肾活血汤治疗增生性骨关节病 28 例[J]陕西中医,2002;23(9):805-806.
[20] 李斌.自拟化骨散治疗增生性膝关节炎 28 例[J]四川中医,2002;20(7):67-68.
[21] 陈本华.祛痹方治疗骨关节炎 35 例临床观察[J]福建中医药,2002;33(l):l3-14.
[22] 吕同杰.略谈增生性关节炎的中医药治疗.山东中医杂志,1984;(1):1-5.
[23] 江蓉星,汪亚强,王志洪.骨关节炎的中医治疗[J].成都中医药大学学报,2001;24(4):11-13.
[24] 陈庚红.新癀片与仙骨葆合用治疗中老年骨关节退行性变的临床观察.[J]中国中西医结合杂志,2002;22(8):586-589.
[25] 吴林生,金嫣丽. 中药及手法治疗膝关节骨性关节炎 121 例疗效分析[J]. 中医杂志,1993,13(12):742-744.
[26] 张建福.骨质增生病的中西医诊疗.北京:中国中医药出版社,1995:59.
[27] 刘洪旺.退行性膝关节骨性关节病的中医辨证施治[J].中国骨伤,1997,10(4):27-29.
[28] 王少山,张世华,邱红明,等.骨病中西医诊疗学.北京:中国中医药出版社,200;218:6-9.
[29] 宏树臣. 中医指针综合治疗膝关节骨性关节炎[J]. 中国骨伤,1998;(5). 19～20-22.
[30] 诸方受.增生性关节炎 22 例疗效观察.中国骨伤,1991;4(3):3-5.
[31] 赵勇.中国骨伤方药大全.北京:学苑出版社,1995 年。187-188.
[32] 单文龙,陈茹琴.独活寄生汤加减治疗骨关节炎 24 例.江苏中医,1993,14(3):11-13.
[33] 金毅.独活寄生汤治疗膝关节骨质增生 30 例.广西中医药,1990;(3):38-40.
[34] 杜见斌.益肝补肾通络法治疗骨性关节炎 96 例.山东中医杂志,1992;11(1):19-20.
[35] 陈星南,陈建良. 补气活血法治疗膝部骨关节炎的临床应用体会[J]. 光明中医,1998;(3). 48～50.
[36] 周有华,裴明秀,毛鹏等.中西医结合治疗膝关节骨性关节炎 75 例.广西中医药,1989;12,(4):13-15.
[37] 范明等.中医治疗膝关节增生性关节炎的临床体会.辽宁中医杂志,1984(12):22-24
[38] 王魁亮.骨痹汤治疗膝关节骨性关节炎 54 例临床观察,新疆中医药.1993;(2):27-29.
[39] 章煜铭.补肾壮筋汤治疗退行性骨关节病 183 例.浙江中医杂志,1992; 27(4): 174-176.
[40] 马素英.应用马氏骨刺丸治疗骨性关节炎 216 例.北京中医杂志,1993;3:49-52.
[41] 陈建鸿.中医中药治疗膝关节骨关节炎 54 例临床体会.中国中医骨伤科,1995;3(6):3611-3613.
[42] 刘德玉.李堪印教授治疗骨性关节炎临床经验.山西中医学院学报.1999;22(1):19-23.
[43] 许书亮,苏友新,林俊仁.骨炎汤治疗膝骨性关节炎 158 例临床研究[J].中国中医骨伤科杂志,2001;9(1):45-46.
[44] 崔连光.壮筋束骨丸治疗骨质增生腰腿痛 62 例.山东中医杂志,1992;11(6):23-25.
[45] 王承训.强骨散治疗颈椎增生 300 例.山东中医杂志,1995;14(7):305-307.
[46] 高学礼.加味苍柏汤治疗增生性关节炎 65 例.山东中医杂志,1991;10(1):22-24.
[47] 施杞.中国中医骨伤科百家方技精华.北京:中国中医出版社,1990;165:45.
[48] 邢峰.自制复方风湿康治疗骨关节炎 68 例临床观察.安徽中医临床杂志,1998;10,10(6):371-372.
[49] 王明武. 骨刺丸治疗骨质增生 133 例报告[J]. 中国中医骨伤科,1995;(1):65-67.
[50] 陈立忠,姬艳波,段瑛春. 自拟益肾强骨汤治疗膝关节骨性关节炎 72 例疗效观察[J]. 中医正骨,1997;(4):231-233.
[51] 陈泽文,喻友军.骨痹汤治疗膝关节骨性关节炎 82 例总结[J]. 湖南中医杂志,2002;(3):87-89.
[52] 孟庆莉,赵生文.补肾祛瘀法治疗骨关节炎 139 例。河南中医,2002;22(2):51-54.
[53] 蒋连泓.“关节消肿止痛冲剂”治疗各种关节炎 102 例疗效观察.天津中医,1992,(4):13-15.
[54] 王敖明,邱德华.石氏调中保元汤治疗老年性膝关节病[J].上海中医药杂志2001;(7):34-35.
[55] 吴永昕,肖泓,吴生元.补中桂枝汤治疗退行性骨关节病 83 例.四川中医,2002;20(2):63-64.
[56] 许建安.二藤汤治疗膝关节骨关节病经验介绍.中国中医骨伤科,1993;(1):34-35.
[57] 赵龙.健膝汤治疗膝关节骨质增生.中国骨伤.1996,9(2):47-49.
[58] 路则显.灵仙汤治疗膝关节骨性关节炎[J].四川中医,1996,14(7):47-50.
[59] 邓伟.养血祛风除湿治疗增生性膝关节炎 50 例[J].实用中医药杂志,1997;13(4):3-5.
[60] 杜天信,韩新峰,高书图.寒湿痹颗粒治疗寒湿痹阻型风湿病的临床观察。中医正骨,2002;14(3):10-12.
[61] 周联耀.中西医结合治疗老年性骨关节炎.中国骨伤,1995,8(5):27-29.
[62] 李强,李同生.健骨汤治疗骨性关节病临床及实验研究.中医正骨,1992,4(3):9-12.
[63] 严培军,孙玉明,周福贻. 从痰瘀水论治膝关节骨性关节炎 176 例[J]. 南京中医药大学学报(自然科学版),2000;(4):249-251.
[64] 雷波,刘定安. 从瘀血痰湿论治膝关节骨关节病 48 例临床观察[J]. 湖南中医杂志,1999;15(2):12-13.
[65] 宋绍亮.张鸣鹤主任医师治疗关节病的经验.山东中医杂志,1991,10(3):44-47.
[66] 宋绍亮.骨疣初探.山东中医杂志,1993;12(3):3-5.
[67] 贺建平.制马钱子散治疗骨质增生及风湿病 108 例.江西中医药,1994,25(4):38-39.
[68] 李汉俊.蚂蚁风湿消治疗腰椎骨关节炎 76 例[J].中国中医药信息杂志,1996;(12):54-56.
[69] 周翠英.蠲水汤治疗膝关节退行性病变合并滑膜炎 42 例. 山东中医杂志,1991;10(3):35-36.
[70] 韩新峰,杜天信,李无阴.湿热痹颗粒治疗湿热痹阻型风湿病的临床观察. 中医正骨,2002;14(4):9-11.
[71] 杨久山,张维文.通痹汤治疗膝骨性关节炎伴关节积液 24 例[J].山东中医药大学学报,2000;24(6):446-447.
[72] 高文香,刘元禄,李永生,等.补肾法防治兔膝关节骨性关节炎的病理形态学观察[J].中医正骨,1999;11(11):13-15.
[73] 高文香,任汉阳,周颖,刘元禄.补肾法与活血法治疗兔膝骨关节炎的病理形态学对比研究.中医正骨,2000;12(6):5-8.
[74] 董建勇,赵晓薇,李立.附桂关节汤防治骨性关节炎作用的形态学观察[J].甘肃中医学院学报,1997,14(1):27-30.
[75] 沈培芝.强筋方治疗骨性关节炎的组织病理学观察研究[J].中国中医骨伤科,1995,3(l):1-3.
[76] 任峰.益气养血通络法(治血痹法)对小鼠骨关节病的实验研究.上海中医药杂志,1994,(7):41-42.
[77] 汪青春,沈培芝,徐宇,石印玉.不同方药治疗膝骨关节炎的组织形态学对比研究.中国中医骨伤科杂志,1998;6(2):1-3.
[78] 王羽丰,许学孟,邓晋丰.补肾活血胶囊影响兔膝关节退变性疾病组织形态学的实验研究.中国中医骨伤科,1999;7(4):9-10.
[79] 王耶,刘建宇,宋艳,等. 丹参和透明质酸钠注射液对骨关节炎治疗作用的实验研究[J].中国生化药物杂志, 1998; 19 (3) :248-251.
[80] 江伟达,郑效文,郑清波,等.中药关节Ⅲ号方治疗家兔膝骨关节炎的实验研究[J].中国中医骨伤科,1994,2(1):1-3.
[81] 毛小兵,邹季.风湿骨痛药酒药槌外治法防治关节软骨退变的实验研究[J].中医正骨,2002;15(4):220-221.
[82] 晏雪生,彭亚琴,明安萍.川芎嗪注射液对体外培养软骨影响的实验研究[J].中国中医骨伤科杂志,2002;10(1):15-17.
[83] 冯伟,石印玉,沈培芝,等.中药对软骨细胞代谢的影响[J].中国中医骨伤杂志,2000;8(2):9-12.
[84] 王国文,潘海东,曲波.参脉注射液对骨关节炎模型动物关节软骨胶原含量的影响[J].中国中医骨伤杂志,2001;9(2):14-16.
[85] 李承军,吴志奎,陈玉英.补肾壮骨药对老年大鼠软骨代谢作用的研究.中药药理与临床,1995,11(1)34-36.
[86] 岳珍,王嘉夫,吕红斌.行气消肿类中药对体外培养的软骨细胞代谢的影响[J].中国运动学杂志,1996,16(1):34-37.
[87] 王济伟,史炜镔,杜宁,等.手法治疗实验性膝骨关节炎的血流动力学研究[J].中国骨伤,1997,10(6):13-15.
[88] 潘海东,曲波,王耶.参麦注射液对骨关节炎动物模型血液中白细胞介素 1 水平的影响[J].中国中医骨伤科杂志,2000;8(1):17-18.
[89] 王拥军,施杞,石印玉等.芪麝颈康丸对颈椎间盘内 IL-12、IL-6、TNFα含量的影响.中国中医骨伤科杂志,2000;8(1):23-26.
[90] 曹月龙,郑昱新,石印玉.养血软坚胶囊治疗膝骨关节炎疗效及安全性评价的随机对照试验[J].中国药物与临床,2004;4(6):423-427.
[91] 马建兵,沙浩渡,李向阳,陈明凡,王晓安. 兔实验性膝骨性关节炎的组织病理学及发病机理[J]. 中国矫形外科杂志,2001;(1):43-45.
[92] 汪青春,董蕙芳,沈培芝,等.中药对膝骨关节炎黑鼠血清 SOD、HA、NO 水平的影响[J].中医正骨,1999;11(5):6-8.
[93] 周尊谦.丹紫康膝冲剂治疗膝关节退行性骨关节病临床观察。中国骨伤,1999;12(12):49-51.
[94] 王毅,邢国胜,于顺禄等。IL-1β诱导软骨细胞培养金属蛋白酶/金属蛋白酶抑制剂水平及药物对其影响.中华风湿病学杂志,2003;7(12):718-721.
[95] 张磊,胡阿威,张功礼等.痹康灵对骨关节炎治疗作用的实验研究,中医正骨,2004;16(7)4-6.
[96] 黄枫,唐勇,郑晓辉.补肾强膝方对绝经后妇女膝骨性关节炎的影响[J].中医正骨,2002;14(4):12-15.
[97] 万荣,杨庆铭,邓廉夫.黑虎丹治疗兔骨关节炎的实验研究[J].中国骨伤,2001;14(2):85-87.
[98] 魏玉玲,刘营杰,梁克玉.消痹灵治疗骨性关节炎的机制探讨.现代康复,2001;5(4):66-67.
[99] 沈霖,沈耀,杨述华.丹参注射液对维甲酸诱导的软骨细胞凋亡的影响[J].中国中医骨伤科杂志,2002;10(5):1-4.